+1-888-308-5802     
News Contact Us

Australia approves Merck’s patent for use of paired CRISPR nickases

Author : Paroma Bhattacharya | Published Date : 2018-08-17 

Merck, the leading pharmaceutical and life science firm, has reportedly announced that it has availed permission for the patent application of paired CRISPR nickases from the Australian Patent Office. Sources claim that Merck's CRISPR integration patent portfolio already boasts of patents granted in Europe, Australia, China, Canada, South Korea, Israel, and Singapore.

According to trusted reports Merck’s IP would be required by commercial organizations for CRISPR-based DNA insertion if the firm needs access to the right defect in the somatic cells of the patient undergoing gene therapy. Merck plans to license this patent soon for various fields.

As per the granted patent application, two CRISPR nickases are targeted to one gene target that act by slashing the opposite strands of the chromosome series to generate a bi-stranded break.

Seeking Alpha reports Udit Batra CEO, Life Science, Merck KGaA to have stated that the allowance for this new patent represents a commendable advancement in CRISPR-enabled therapeutics safety. The paired nickase CRISPR technology is particularly important for the research community that requires extremely accurate methods during the development of treatment methodologies for difficult-to-treat diseases, he further affirms.

For the uninitiated, Merck was the first company that incepted custom biomolecules for genome editing across the globe (TargeTron™ RNA-guided group II introns & CompoZr™ zinc finger nucleases), motivating the overall R&D community to adopt this technique.

According to sources, the Australian Patent Office has not only approved the patent application for paired nickases but has also declared the grant for Merck's CRISPR integration 2017 patent after four anonymously filed petitions were withdrawn.

For the record, Merck KGaA is also the first company of its kind to have manufactured arrayed CRISPR libraries that reportedly cover the whole genome, allowing for a faster cure as scientists can precisely analyze the root cause of the disease.

About Author

Paroma Bhattacharya

Paroma Bhattacharya

Paroma Bhattacharya, having completed her post-graduation in Journalism and Mass Communication, started her career in writing with resourceful and informative content development across diverse fields. Having dealt in myriad topics ranging from business to real estate, she now pens down articles for fractovia.org and other portals. She can be contacted at- [email protected] | https://twitter.com/paromab1

Related News

Snapsheet closes its Series E investment round at $29 million

Published Date: 2019-05-21         Author: Paroma Bhattacharya

The funding would be further accelerating the company’s ongoing efforts of facilitating wider claims management solutions on a global level. Following the Series E round, the total capital raised by the company has reached the $71 million mark. Snapsheet, a renowned pioneer of virtua... Read More

Brazilian court lifts one of two restrictions on Norsk Hydro plant

Published Date: 2019-05-18         Author: Paroma Bhattacharya

The federal court in Belem, Brazil has reportedly lifted one of two production restrictions on a key plant owned by Norsk Hydro, the Norwegian metal manufacturer said in a statement. As per trusted sources, the Alunorte alumina refinery, which is a main supplier to the aluminum industry, presentl... Read More

Lotus works on hypercar with expansion in Midlands & 200 new staff

Published Date: 2019-05-13         Author: Paroma Bhattacharya

Lotus, the British sports car manufacturer, recently announced that it will be hiring 200 engineers as it seeks to triple its yearly car production capacity. Reliable reports cite that the car manufacturer, in a bid to reinvent itself, will be increasing its car production to 5,000 per year with ... Read More

© 2019 Fractovia. All Rights Reserved